We advised Immatics on the offering of shares

Davis Polk advised Immatics N.V. in connection with its $201 million SEC-registered offering of ordinary shares. The ordinary shares are listed on Nasdaq under the symbol “IMTX.”

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for its pipeline of adoptive cell therapies and TCR bispecifics as well as its partnerships with global leaders in the pharmaceutical industry. Immatics is committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

The Davis Polk corporate team included partner Yasin Keshvargar and associates David Li and Vivian Liu. Counsel Christopher A. Baratta and associates Justin Corvino and Caleb E. Smith provided tax advice. Partner David R. Bauer and associate Adrian Rabin provided intellectual property advice. All members of the Davis Polk team are based in the New York office.